ArticleAntibiotics (Basel, Switzerland)2022
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.Virology journal · 2020Pooled it
- Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.Indian journal of pharmacologyPooled it
- Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting.International journal of general medicine · 2022Trial
- Observational
- Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration.International journal of nanomedicine · 2025Article
- Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.Pharmacology research & perspectives · 2024Article
- Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19.Inflammopharmacology · 2024Article
- Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.International journal of general medicine · 2024Article
- Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV).Scientific reports · 2023Article
- The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2023Observational
- Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand.The Lancet regional health. Southeast Asia · 2023Article
- An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of CareInfection & chemotherapy · 2023Article
- COVID-19 signalome: Potential therapeutic interventions.Cellular signalling · 2023Review
- A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors.Current issues in molecular biology · 2023Review
- Favipiravir-Tautomeric and Complexation Properties in Solution.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?GeroScience · 2022Article
- Article
- Perspective: repurposed drugs for COVID-19.Archives of medical science : AMS · 2022Article
- Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.International journal of clinical practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for treating COVID-19 are limited. We conducted a retrospective observational study of hospitalized adult patients with COVID-19 at five tertiary care hospitals in Thailand. We reviewed patient charts to obtain all necessary data. Among 247 COVID-19 patients, 63 (23.0%) received ≥1 dose of favipiravir. Of these 63 patients, 61.9% were male with a median age of 48 years (range 22-85 years), 27.0% required an O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.